Mixed results for BMS’ Opdivo, Yervoy combo in kidney cancer

16th August 2017 Uncategorised 0

A combination of Bristol-Myers Squibb’s Opdivo and Yervoy has failed to significantly improve progression-free survival (PFS) compared to Pfizer’s Sutent in patients with renal cancer.

More: Mixed results for BMS’ Opdivo, Yervoy combo in kidney cancer
Source: News